Related Experiment Video

Updated: Aug 8, 2026

Cholesterol Efflux Assay
07:54

Cholesterol Efflux Assay

Published on: March 6, 2012

FXR: a target for cholestatic syndromes?

Shi-Ying Cai1, James L Boyer

  • 1Liver Center, Department of Medicine, Yale University School of Medicine, P.O. Box 208019, New Haven, CT 06520-8019, USA.

Expert Opinion on Therapeutic Targets
|May 19, 2006
PubMed

Insights

The nuclear farnesoid X receptor (FXR) regulates bile acid balance. FXR ligand therapy is explored for cholestatic liver diseases, addressing gene regulation and potential concerns.

Area of Science:

  • Hepatology and Molecular Biology
  • Endocrinology
  • Gastroenterology

Background:

  • The nuclear farnesoid X receptor (FXR) is crucial for bile acid homeostasis in humans.
  • FXR regulates key genes in bile acid synthesis, metabolism, and transport (e.g., CYP7A1, BSEP, MDR3).
  • Dysregulation of these genes is implicated in cholestatic liver diseases.

Purpose of the Study:

  • To review the therapeutic rationale for using FXR ligand therapy in cholestatic liver disorders.
  • To discuss the potential benefits and concerns associated with FXR-targeted treatments.

Main Methods:

  • Literature review of studies on FXR function in bile acid homeostasis.
  • Analysis of gene expression patterns in cholestatic liver diseases.
  • Examination of clinical data and preclinical findings related to FXR agonists.

Main Results:

  • FXR activation influences multiple genes critical for bile acid transport and metabolism.
  • Targeting FXR offers a potential strategy for managing cholestatic conditions.
  • Understanding FXR's role is key to developing effective therapies.

Conclusions:

  • FXR ligand therapy presents a promising avenue for treating cholestatic liver diseases.
  • Further research is needed to fully elucidate the risks and benefits.
  • Personalized approaches may be required for optimal FXR-based treatment.

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
Chronic Bowel Disorders: Introduction01:17

Chronic Bowel Disorders: Introduction

Chronic bowel diseases are a group of long-term conditions affecting the digestive tract, characterized by inflammation and damage to the gut lining. These conditions primarily include irritable bowel syndrome and inflammatory bowel disease.
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
Transducer Mechanism: Nuclear Receptors01:31

Transducer Mechanism: Nuclear Receptors

Nuclear receptors, or NRs, are unique transcription factors that regulate gene transcription and affect the cellular pathways involved in reproduction, development, or metabolism. Their ability to be stimulated by small lipophilic ligands and control vital cellular processes makes them ideal drug targets. Nearly 10-15% of currently prescribed drugs target these receptors.
About 48 different soluble family members of nuclear receptors are identified that can be divided into two main classes:
Cholecystitis01:20

Cholecystitis

Cholecystitis is inflammation of the gallbladder, most commonly caused by obstruction of the cystic duct. This blockage prevents bile from draining, leading to gallbladder distension, inflammation, and potentially serious complications. This condition may present acutely or chronically and can happen with or without gallstones.EtiologyAbout 95% of cholecystitis cases are calculous, caused by gallstones blocking the cystic duct, leading to bile accumulation and inflammation of the gallbladder...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...